_id
691311ddccc777a4e85d7f00
Ticker
LXEO
Name
Lexeo Therapeutics, Inc. Common Stock
Exchange
NASDAQ
Address
345 Park Avenue South, New York, NY, United States, 10010
Country
USA
Sector
Healthcare
Industry
Biotechnology
Currency
USD
Website
https://www.lexeotx.com
Description
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Last Close
9.95
Volume
1129219
Current Price
10.54
Change
-0.32
Last Updated
2026-01-05T10:00:40.090Z
Image
data:image/webp;base64,UklGRhoBAABXRUJQVlA4WAoAAAAQAAAAPwAAPwAAQUxQSFwAAAABYFJte5WdSSQ5iEAb5L0Kap4cNBgFqIHbBf4A7/kUJiJyxwMecZMv8hU3+Qe/8AF38h538i3e4wdu8gV/cft9X7ziJp/wG9/wBne4x518h4/4iZt8li+4yUc84FZQOCCYAAAAcAYAnQEqQABAAD6lSppJpiUioTf4CADAFIlAGdv/j12l/9qu3/wFuzMqxgWtPduDw3/yWYTrNtRrsWYAAP3J2fZiPR4jAiEP/ahyfNkZsr9/+xMXfrsVLYWobyLNThIHjClFaInr8UKi9FkpWqWmaxBGSTrF1C7T9V9bQNfh5bjYWwRX90e5LCVOpX6Pc96i48UHIglAAAA=
Ipo Date
2023-11-03T00:00:00.000Z
Market Cap
701408192
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
0.993
Sentiment Sources
3
Rating
4.5714
Target Price
19.9091
Strong Buy
4
Buy
3
Hold
0
Sell
0
Strong Sell
0
Current Quarter
2025-09-30
Revenue
0
Cost Of Revenue
530000
Gross Profit
-530000
Operating Expenses
21118000
Operating Income
-21648000
Interest Expense
22000
Pretax Income
-20283000
Net Income
-20283000
Eps
-0.332612522547441
Dividends Per Share
-
Shares Outstanding
72987327
Income Tax Expense
-
EBITDA
-19731000
Operating Margin
-
Total Other Income Expense Net
1365000
Cash
40996000
Short Term Investments
81768000
Receivables
-
Inventories
-
Total Current Assets
127793000
Property Plant Equipment
9413000
Total Assets
143844000
Payables
4656000
Short Term Debt
2715000
Long Term Debt
-
Total Liabilities
23013000
Equity
120831000
Bs_currency_symbol
USD
Depreciation
530000
Change In Working Capital
-12505000
Cash From Operations
-29547000
Capital Expenditures
289000
Cash From Investing
35011000
Cash From Financing
52000
Net Change In Cash
5516000
Cf_currency_symbol
USD
PE
-
PB
5.31931655105064
ROE
-16.786255182858703
ROA
-14.100692416784849
FCF
-29836000
Fcf Percent
-
Piotroski FScore
0
Health Score
37
Deep Value Investing Score
3.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
4.3
Garp Investing Score
2
Growth Investing Score
0.5
Momentum Investing Score
2.5
Net Net Investing Score
2.5
Quality Investing Score
3
Value Investing Score
3.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
0
Quarters > 0 > income Statement > cost Of Revenue
530000
Quarters > 0 > income Statement > gross Profit
-530000
Quarters > 0 > income Statement > operating Expenses
21118000
Quarters > 0 > income Statement > operating Income
-21648000
Quarters > 0 > income Statement > interest Expense
22000
Quarters > 0 > income Statement > pretax Income
-20283000
Quarters > 0 > income Statement > net Income
-20283000
Quarters > 0 > income Statement > eps
-0.332612522547441
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
60980867
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-19731000
Quarters > 0 > income Statement > operating Margin
-
Quarters > 0 > income Statement > total Other Income Expense Net
1365000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
40996000
Quarters > 0 > balance Sheet > short Term Investments
81768000
Quarters > 0 > balance Sheet > receivables
-
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
127793000
Quarters > 0 > balance Sheet > property Plant Equipment
9413000
Quarters > 0 > balance Sheet > total Assets
143844000
Quarters > 0 > balance Sheet > payables
4656000
Quarters > 0 > balance Sheet > short Term Debt
2715000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
23013000
Quarters > 0 > balance Sheet > equity
120831000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-20283000
Quarters > 0 > cash Flow > depreciation
530000
Quarters > 0 > cash Flow > change In Working Capital
-12505000
Quarters > 0 > cash Flow > cash From Operations
-29547000
Quarters > 0 > cash Flow > capital Expenditures
289000
Quarters > 0 > cash Flow > cash From Investing
35011000
Quarters > 0 > cash Flow > cash From Financing
52000
Quarters > 0 > cash Flow > net Change In Cash
5516000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.332612522547441
Quarters > 0 > ratios > PB
5.31931655105064
Quarters > 0 > ratios > ROE
-16.786255182858703
Quarters > 0 > ratios > ROA
-14.100692416784849
Quarters > 0 > ratios > FCF
-29836000
Quarters > 0 > ratios > Piotroski FScore
0
Quarters > 0 > ratios > fcf Percent
-
Quarters > 0 > health Score
37
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
510000
Quarters > 1 > income Statement > gross Profit
-510000
Quarters > 1 > income Statement > operating Expenses
30178000
Quarters > 1 > income Statement > operating Income
-30688000
Quarters > 1 > income Statement > interest Expense
59000
Quarters > 1 > income Statement > pretax Income
-26103000
Quarters > 1 > income Statement > net Income
-26103000
Quarters > 1 > income Statement > eps
-0.5990550063905626
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
43573628
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-25534000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
4585000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
35480000
Quarters > 1 > balance Sheet > short Term Investments
97413000
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
140062000
Quarters > 1 > balance Sheet > property Plant Equipment
9755000
Quarters > 1 > balance Sheet > total Assets
176068000
Quarters > 1 > balance Sheet > payables
20025000
Quarters > 1 > balance Sheet > short Term Debt
2656000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
37850000
Quarters > 1 > balance Sheet > equity
138218000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-26103000
Quarters > 1 > cash Flow > depreciation
510000
Quarters > 1 > cash Flow > change In Working Capital
-1341000
Quarters > 1 > cash Flow > cash From Operations
-27219000
Quarters > 1 > cash Flow > capital Expenditures
108000
Quarters > 1 > cash Flow > cash From Investing
-39174000
Quarters > 1 > cash Flow > cash From Financing
72960000
Quarters > 1 > cash Flow > net Change In Cash
6567000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.5990550063905626
Quarters > 1 > ratios > PB
3.322765769436687
Quarters > 1 > ratios > ROE
-18.88538395867398
Quarters > 1 > ratios > ROA
-14.825521957425542
Quarters > 1 > ratios > FCF
-27327000
Quarters > 1 > ratios > Piotroski FScore
0
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
37
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
0
Quarters > 2 > income Statement > cost Of Revenue
501000
Quarters > 2 > income Statement > gross Profit
-501000
Quarters > 2 > income Statement > operating Expenses
33805000
Quarters > 2 > income Statement > operating Income
-33805000
Quarters > 2 > income Statement > interest Expense
28000
Quarters > 2 > income Statement > pretax Income
-32656000
Quarters > 2 > income Statement > net Income
-32656000
Quarters > 2 > income Statement > eps
-0.986169259996477
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
33113991
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-32115000
Quarters > 2 > income Statement > operating Margin
-
Quarters > 2 > income Statement > total Other Income Expense Net
1149000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
28913000
Quarters > 2 > balance Sheet > short Term Investments
70918000
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
105274000
Quarters > 2 > balance Sheet > property Plant Equipment
10133000
Quarters > 2 > balance Sheet > total Assets
125690000
Quarters > 2 > balance Sheet > payables
11981000
Quarters > 2 > balance Sheet > short Term Debt
2647000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
37575000
Quarters > 2 > balance Sheet > equity
88115000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-32656000
Quarters > 2 > cash Flow > depreciation
501000
Quarters > 2 > cash Flow > change In Working Capital
6730000
Quarters > 2 > cash Flow > cash From Operations
-21716000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
15600000
Quarters > 2 > cash Flow > cash From Financing
11000
Quarters > 2 > cash Flow > net Change In Cash
-6105000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.986169259996477
Quarters > 2 > ratios > PB
3.960976736537479
Quarters > 2 > ratios > ROE
-37.06065936560177
Quarters > 2 > ratios > ROA
-25.981382767125467
Quarters > 2 > ratios > FCF
-21716000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-
Quarters > 2 > health Score
38
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
1944000
Quarters > 3 > income Statement > cost Of Revenue
-
Quarters > 3 > income Statement > gross Profit
972000
Quarters > 3 > income Statement > operating Expenses
27382000
Quarters > 3 > income Statement > operating Income
-27382000
Quarters > 3 > income Statement > interest Expense
30000
Quarters > 3 > income Statement > pretax Income
-25924000
Quarters > 3 > income Statement > net Income
-25924000
Quarters > 3 > income Statement > eps
-0.7837685061533719
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
33076093
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-25373000
Quarters > 3 > income Statement > operating Margin
-1408.5390946502057
Quarters > 3 > income Statement > total Other Income Expense Net
1458000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
35014000
Quarters > 3 > balance Sheet > short Term Investments
86504000
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
126121000
Quarters > 3 > balance Sheet > property Plant Equipment
10557000
Quarters > 3 > balance Sheet > total Assets
146942000
Quarters > 3 > balance Sheet > payables
6417000
Quarters > 3 > balance Sheet > short Term Debt
2670000
Quarters > 3 > balance Sheet > long Term Debt
-
Quarters > 3 > balance Sheet > total Liabilities
30100000
Quarters > 3 > balance Sheet > equity
116842000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-25924000
Quarters > 3 > cash Flow > depreciation
521000
Quarters > 3 > cash Flow > change In Working Capital
-6407000
Quarters > 3 > cash Flow > cash From Operations
-28326000
Quarters > 3 > cash Flow > capital Expenditures
13000
Quarters > 3 > cash Flow > cash From Investing
-93583000
Quarters > 3 > cash Flow > cash From Financing
-97000
Quarters > 3 > cash Flow > net Change In Cash
-122006000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.7837685061533719
Quarters > 3 > ratios > PB
2.983704662878074
Quarters > 3 > ratios > ROE
-22.187227195700178
Quarters > 3 > ratios > ROA
-17.642335070980387
Quarters > 3 > ratios > FCF
-28339000
Quarters > 3 > ratios > Piotroski FScore
0
Quarters > 3 > ratios > fcf Percent
-14.577674897119342
Quarters > 3 > health Score
34
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
2001999
Annuals > 0 > income Statement > gross Profit
-2001999
Annuals > 0 > income Statement > operating Expenses
105766000
Annuals > 0 > income Statement > operating Income
-105766000
Annuals > 0 > income Statement > interest Expense
114000
Annuals > 0 > income Statement > pretax Income
-98333000
Annuals > 0 > income Statement > net Income
-98333000
Annuals > 0 > income Statement > eps
-3.09344955850715
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
31787491
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-96194000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
7433000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
35014000
Annuals > 0 > balance Sheet > short Term Investments
86504000
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
126121000
Annuals > 0 > balance Sheet > property Plant Equipment
10557000
Annuals > 0 > balance Sheet > total Assets
146942000
Annuals > 0 > balance Sheet > payables
6417000
Annuals > 0 > balance Sheet > short Term Debt
2670000
Annuals > 0 > balance Sheet > long Term Debt
-
Annuals > 0 > balance Sheet > total Liabilities
30100000
Annuals > 0 > balance Sheet > equity
116842000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-98333000
Annuals > 0 > cash Flow > depreciation
2001999
Annuals > 0 > cash Flow > change In Working Capital
2729000
Annuals > 0 > cash Flow > cash From Operations
-81151000
Annuals > 0 > cash Flow > capital Expenditures
481000
Annuals > 0 > cash Flow > cash From Investing
-94077000
Annuals > 0 > cash Flow > cash From Financing
88776000
Annuals > 0 > cash Flow > net Change In Cash
-86452000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-3.09344955850715
Annuals > 0 > ratios > PB
2.6144518966638706
Annuals > 0 > ratios > ROE
-84.15894969274747
Annuals > 0 > ratios > ROA
-66.91960093097957
Annuals > 0 > ratios > FCF
-81632000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
34
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
1843000
Annuals > 1 > income Statement > gross Profit
-1843000
Annuals > 1 > income Statement > operating Expenses
68513000
Annuals > 1 > income Statement > operating Income
-68513000
Annuals > 1 > income Statement > interest Expense
205000
Annuals > 1 > income Statement > pretax Income
-66394000
Annuals > 1 > income Statement > net Income
-66394000
Annuals > 1 > income Statement > eps
-2.491670725379637
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
26646378
Annuals > 1 > income Statement > income Tax Expense
-1
Annuals > 1 > income Statement > EBITDA
-64346000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
2119000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
121466000
Annuals > 1 > balance Sheet > short Term Investments
0
Annuals > 1 > balance Sheet > receivables
-
Annuals > 1 > balance Sheet > inventories
-
Annuals > 1 > balance Sheet > total Current Assets
124294000
Annuals > 1 > balance Sheet > property Plant Equipment
12261000
Annuals > 1 > balance Sheet > total Assets
139807000
Annuals > 1 > balance Sheet > payables
3794000
Annuals > 1 > balance Sheet > short Term Debt
2605000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
26272000
Annuals > 1 > balance Sheet > equity
113535000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-66394000
Annuals > 1 > cash Flow > depreciation
1843000
Annuals > 1 > cash Flow > change In Working Capital
1482000
Annuals > 1 > cash Flow > cash From Operations
-59496000
Annuals > 1 > cash Flow > capital Expenditures
165000
Annuals > 1 > cash Flow > cash From Investing
-165000
Annuals > 1 > cash Flow > cash From Financing
103791000
Annuals > 1 > cash Flow > net Change In Cash
44130000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-2.491670725379637
Annuals > 1 > ratios > PB
2.255442749636676
Annuals > 1 > ratios > ROE
-58.47888316378209
Annuals > 1 > ratios > ROA
-47.48975373193044
Annuals > 1 > ratios > FCF
-59661000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
34
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
654000
Annuals > 2 > income Statement > cost Of Revenue
1145000
Annuals > 2 > income Statement > gross Profit
654000
Annuals > 2 > income Statement > operating Expenses
61163000
Annuals > 2 > income Statement > operating Income
-60509000
Annuals > 2 > income Statement > interest Expense
91000
Annuals > 2 > income Statement > pretax Income
-59277000
Annuals > 2 > income Statement > net Income
-59277000
Annuals > 2 > income Statement > eps
-2.3551284325111896
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
25169328
Annuals > 2 > income Statement > income Tax Expense
89000
Annuals > 2 > income Statement > EBITDA
-58041000
Annuals > 2 > income Statement > operating Margin
-9252.140672782874
Annuals > 2 > income Statement > total Other Income Expense Net
1232000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
77335000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
-
Annuals > 2 > balance Sheet > inventories
-
Annuals > 2 > balance Sheet > total Current Assets
80048000
Annuals > 2 > balance Sheet > property Plant Equipment
13775000
Annuals > 2 > balance Sheet > total Assets
97076000
Annuals > 2 > balance Sheet > payables
2678000
Annuals > 2 > balance Sheet > short Term Debt
2834000
Annuals > 2 > balance Sheet > long Term Debt
-
Annuals > 2 > balance Sheet > total Liabilities
210030000
Annuals > 2 > balance Sheet > equity
-112954000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-59277000
Annuals > 2 > cash Flow > depreciation
1145000
Annuals > 2 > cash Flow > change In Working Capital
1791000
Annuals > 2 > cash Flow > cash From Operations
-54560000
Annuals > 2 > cash Flow > capital Expenditures
901000
Annuals > 2 > cash Flow > cash From Investing
-901000
Annuals > 2 > cash Flow > cash From Financing
189000
Annuals > 2 > cash Flow > net Change In Cash
-55272000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-2.3551284325111896
Annuals > 2 > ratios > PB
-2.141378278591285
Annuals > 2 > ratios > ROE
52.478885209908455
Annuals > 2 > ratios > ROA
-61.062466521076274
Annuals > 2 > ratios > FCF
-55461000
Annuals > 2 > ratios > Piotroski FScore
0
Annuals > 2 > ratios > fcf Percent
-84.80275229357798
Annuals > 2 > health Score
30
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
1657000
Annuals > 3 > income Statement > cost Of Revenue
13405
Annuals > 3 > income Statement > gross Profit
1657000
Annuals > 3 > income Statement > operating Expenses
52294000
Annuals > 3 > income Statement > operating Income
-50637000
Annuals > 3 > income Statement > interest Expense
0
Annuals > 3 > income Statement > pretax Income
-50622000
Annuals > 3 > income Statement > net Income
-50622000
Annuals > 3 > income Statement > eps
-2.01125751152355
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
25169328
Annuals > 3 > income Statement > income Tax Expense
-155
Annuals > 3 > income Statement > EBITDA
-50609000
Annuals > 3 > income Statement > operating Margin
-3055.944477972239
Annuals > 3 > income Statement > total Other Income Expense Net
15000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
135860000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
-
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
136684000
Annuals > 3 > balance Sheet > property Plant Equipment
174000
Annuals > 3 > balance Sheet > total Assets
136860000
Annuals > 3 > balance Sheet > payables
3061000
Annuals > 3 > balance Sheet > short Term Debt
4312000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
192462000
Annuals > 3 > balance Sheet > equity
-55602000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-50622000
Annuals > 3 > cash Flow > depreciation
13000
Annuals > 3 > cash Flow > change In Working Capital
6041000
Annuals > 3 > cash Flow > cash From Operations
-44182000
Annuals > 3 > cash Flow > capital Expenditures
188000
Annuals > 3 > cash Flow > cash From Investing
-188000
Annuals > 3 > cash Flow > cash From Financing
150857000
Annuals > 3 > cash Flow > net Change In Cash
106487000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-2.01125751152355
Annuals > 3 > ratios > PB
-4.350153629006151
Annuals > 3 > ratios > ROE
91.04348764432935
Annuals > 3 > ratios > ROA
-36.988163086365624
Annuals > 3 > ratios > FCF
-44370000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-26.777308388654195
Annuals > 3 > health Score
30
Valuation > metrics > PE
-0.332612522547441
Valuation > metrics > PB
5.31931655105064
Valuation > final Score
26.806834489493596
Valuation > verdict
77.3% Overvalued
Profitability > metrics > ROE
-16.786255182858703
Profitability > metrics > ROA
-15.871761364080974
Profitability > final Score
15
Profitability > verdict
Weak
Risk > metrics > Debt Equity
0.1904560915659061
Risk > metrics > Interest Coverage
-984
Risk > final Score
-3876
Risk > verdict
High
Liquidity > metrics > Current Ratio
17.337267670601005
Liquidity > metrics > Quick Ratio
17.337267670601005
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
46.77234230563313
Prev Valuations > 1
40.39023263462521
Prev Valuations > 2
80
Prev Profitabilities > 0
15
Prev Profitabilities > 1
15
Prev Profitabilities > 2
0
Prev Risks > 0
-2021
Prev Risks > 1
-4769
Prev Risks > 2
-3591
Prev Liquidities > 0
100
Prev Liquidities > 1
100
Prev Liquidities > 2
100
Updated At
2026-01-20T22:09:59.208Z
Earnings History > 0 > period
2025-09-30
Earnings History > 0 > report Date
2025-11-05
Earnings History > 0 > date
2025-09-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
-
Earnings History > 0 > eps Actual
-0.33
Earnings History > 0 > eps Estimate
-0.84
Earnings History > 0 > eps Difference
0.51
Earnings History > 0 > surprise Percent
60.7143
Earnings History > 1 > period
2025-06-30
Earnings History > 1 > report Date
2025-08-14
Earnings History > 1 > date
2025-06-30
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
-
Earnings History > 1 > eps Actual
-0.6
Earnings History > 1 > eps Estimate
-0.91
Earnings History > 1 > eps Difference
0.31
Earnings History > 1 > surprise Percent
34.0659
Earnings History > 2 > period
2025-03-31
Earnings History > 2 > report Date
2025-05-12
Earnings History > 2 > date
2025-03-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
-
Earnings History > 2 > eps Actual
-0.99
Earnings History > 2 > eps Estimate
-0.89
Earnings History > 2 > eps Difference
-0.1
Earnings History > 2 > surprise Percent
-11.236
Earnings History > 3 > period
2024-12-31
Earnings History > 3 > report Date
2025-03-24
Earnings History > 3 > date
2024-12-31
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
-
Earnings History > 3 > eps Actual
-0.78
Earnings History > 3 > eps Estimate
-0.72
Earnings History > 3 > eps Difference
-0.06
Earnings History > 3 > surprise Percent
-8.3333
Earnings History > 4 > period
2024-09-30
Earnings History > 4 > report Date
2024-11-13
Earnings History > 4 > date
2024-09-30
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
-0.89
Earnings History > 4 > eps Estimate
-0.72
Earnings History > 4 > eps Difference
-0.17
Earnings History > 4 > surprise Percent
-23.6111
Earnings History > 5 > period
2024-06-30
Earnings History > 5 > report Date
2024-08-12
Earnings History > 5 > date
2024-06-30
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.64
Earnings History > 5 > eps Estimate
-0.77
Earnings History > 5 > eps Difference
0.13
Earnings History > 5 > surprise Percent
16.8831
Earnings History > 6 > period
2024-03-31
Earnings History > 6 > report Date
2024-05-09
Earnings History > 6 > date
2024-03-31
Earnings History > 6 > before After Market
BeforeMarket
Earnings History > 6 > currency
USD
Earnings History > 6 > eps Actual
-0.77
Earnings History > 6 > eps Estimate
-0.77
Earnings History > 6 > eps Difference
0
Earnings History > 6 > surprise Percent
0
Earnings History > 7 > period
2023-12-31
Earnings History > 7 > report Date
2024-03-11
Earnings History > 7 > date
2023-12-31
Earnings History > 7 > before After Market
BeforeMarket
Earnings History > 7 > currency
USD
Earnings History > 7 > eps Actual
-0.85
Earnings History > 7 > eps Estimate
-0.73
Earnings History > 7 > eps Difference
-0.12
Earnings History > 7 > surprise Percent
-16.4384
Earnings History > 8 > period
2023-09-30
Earnings History > 8 > report Date
2023-12-11
Earnings History > 8 > date
2023-09-30
Earnings History > 8 > before After Market
BeforeMarket
Earnings History > 8 > currency
USD
Earnings History > 8 > eps Actual
-12.36
Earnings History > 8 > eps Estimate
-2.6
Earnings History > 8 > eps Difference
-9.76
Earnings History > 8 > surprise Percent
-375.3846
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AChart Watch: Is LXEO stock forming a triangle pattern - 2025 Technical Patterns & Smart Allocation Stock Tips baoquankhu1.vn
Read more →Oppenheimer reiterates Outperform rating on Lexeo Therapeutics stock By Investing.com Investing.com South Africa
Read more →Showing 2 of 10
(Last Updated 2025-09-30)
Rating:
STRONG BUY
Target Price:
$19.9091
Analyst Picks
Strong Buy
4
Buy
3
Hold
0
Sell
0
Strong Sell
0
Sentiment:
Bullish
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very High
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very Low
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Debt to Equity
-
Very High
Low ≥ 1
High ≤ 0.3
* Institutions hold a combined 0.00% of the total shares of Lexeo Therapeutics, Inc. Common Stock
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2025-09-30
EPS Actual
-0.33
EPS Estimate
-0.84
EPS Difference
0.51
Surprise Percent
60.7143%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.